All stocks
SUNPHARMA
Large CapSun Pharmaceutical · Pharma
₹1,894.4
-1.13% today
Market Cap
₹4,45,000 Cr
CMP
₹1,894.4
52W High
₹2,625.7
52W Low
₹1,342
P/E
38.2
P/B
6.4
ROCE
18.9%
Div Yield
0.76%
Peer comparison
6 companies · Pharma and nearest by size. Current company highlighted — click a header to sort.
| Company | CMP | MCap (Cr) | P/E | P/B | ROCE | ROE | D/E | Sales 3Y | Profit 3Y | OPM | Div Yld |
|---|---|---|---|---|---|---|---|---|---|---|---|
| LT | ₹4,056 | 5,05,000 | 34.5 | 5.2 | 15.8% | 15.2% | 1.12 | +14.9% | +14.1% | 20.7% | 0.38% |
| SUNPHARMA | ₹1,945 | 4,45,000 | 38.2 | 6.4 | 18.9% | 16.8% | 0.04 | +16.6% | +22.4% | 24.1% | 0.76% |
| MARUTI | ₹14,037 | 3,90,000 | 28.6 | 4.6 | 21.2% | 16.1% | 0.01 | +18.9% | +19% | 26.4% | 0.71% |
| LUPIN | ₹2,363.5 | 92,000 | 34.2 | 5.1 | 18.2% | 16.4% | 0.12 | +16.8% | +19.3% | 23.8% | 0.85% |
| AUROPHARMA | ₹1,658 | 78,000 | 21.8 | 2.6 | 14.1% | 12.8% | 0.18 | +14.2% | +11.4% | 18.4% | 1.13% |
| GRANULES | ₹873.85 | 14,000 | 28.2 | 3.8 | 16.8% | 14.1% | 0.32 | +16% | +18.5% | 21.2% | 1.53% |
Quarterly results
Last 8 quarters (₹ Cr unless noted)
| Quarter | Revenue | Op Profit | OPM | Other Inc | Interest | Dep | PBT | Tax | Net Profit | EPS | QoQ | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Q3 FY25 | 15,065 | 3,706 | 24.6% | 255 | 86 | 409 | 3,467 | 867 | 2,599 | 11.36 | — | — |
| Q4 FY25 | 15,166 | 3,562 | 23.5% | 203 | 125 | 447 | 3,194 | 765 | 2,428 | 10.61 | -6.6% | — |
| Q1 FY26 | 15,645 | 3,512 | 22.4% | 235 | 172 | 509 | 3,066 | 791 | 2,274 | 9.94 | -6.3% | — |
| Q2 FY26 | 15,721 | 3,676 | 23.4% | 200 | 98 | 615 | 3,163 | 732 | 2,430 | 10.62 | +6.9% | — |
| Q3 FY26 | 16,627 | 4,106 | 24.7% | 255 | 139 | 457 | 3,766 | 963 | 2,803 | 12.25 | +15.3% | +7.8% |
| Q4 FY26 | 17,046 | 4,251 | 24.9% | 189 | 135 | 651 | 3,654 | 820 | 2,833 | 12.38 | +1.1% | +16.7% |
| Q1 FY27 | 18,015 | 4,250 | 23.6% | 247 | 186 | 415 | 3,896 | 896 | 3,000 | 13.11 | +5.9% | +31.9% |
| Q2 FY27 | 18,017 | 4,282 | 23.8% | 340 | 147 | 711 | 3,764 | 905 | 2,859 | 12.5 | -4.7% | +17.7% |
Profit & Loss — Annual
Last 4 years (₹ Cr)
| Year | Revenue | Op Profit | OPM | Net Profit | EPS | Tax Rate | Sales Growth | Profit Growth |
|---|---|---|---|---|---|---|---|---|
| FY23 | 63,092 | 14,712 | 23.3% | 9,128 | 39.9 | 24.9% | — | — |
| FY24 | 72,922 | 17,313 | 23.7% | 11,717 | 51.21 | 22.3% | +15.6% | +28.4% |
| FY25 | 86,266 | 21,176 | 24.5% | 14,770 | 64.56 | 22.7% | +18.3% | +26.1% |
| FY26 | 99,945 | 24,119 | 24.1% | 16,754 | 73.23 | 22.8% | +15.9% | +13.4% |
Balance sheet
Last 8 quarters (₹ Cr)
| Quarter | Share Capital | Reserves | Borrowings | Other Liab | Fixed Assets | CWIP | Investments | Other Assets | Total |
|---|---|---|---|---|---|---|---|---|---|
| Q3 FY25 | 3,477 | 60,198 | 2,694 | 15,446 | 33,883 | 2,458 | 18,946 | 26,528 | 81,815 |
| Q4 FY25 | 3,477 | 61,298 | 3,015 | 20,547 | 31,786 | 4,455 | 21,144 | 30,953 | 88,337 |
| Q1 FY26 | 3,477 | 62,869 | 2,731 | 17,828 | 36,263 | 3,228 | 19,246 | 28,168 | 86,905 |
| Q2 FY26 | 3,477 | 64,529 | 2,904 | 20,405 | 31,145 | 2,763 | 18,235 | 39,172 | 91,314 |
| Q3 FY26 | 3,477 | 66,630 | 2,674 | 17,985 | 33,474 | 4,085 | 20,620 | 32,587 | 90,766 |
| Q4 FY26 | 3,477 | 67,703 | 2,948 | 15,129 | 32,100 | 4,010 | 19,443 | 33,704 | 89,257 |
| Q1 FY27 | 3,477 | 69,856 | 2,617 | 15,182 | 34,811 | 2,795 | 19,501 | 34,025 | 91,131 |
| Q2 FY27 | 3,477 | 72,282 | 2,512 | 15,868 | 38,456 | 3,403 | 17,647 | 34,634 | 94,140 |
Cash flow
| Year | Operating | Investing | Financing | Net |
|---|---|---|---|---|
| FY23 | 10,961 | -5,654 | -7,670 | -2,363 |
| FY24 | 13,487 | -13,374 | -9,237 | -9,124 |
| FY25 | 16,028 | -15,520 | -4,830 | -4,322 |
| FY26 | 18,995 | -12,711 | -8,978 | -2,694 |
Shareholding pattern
PromoterGovtFIIDIIPublicOthers
Q3'25
Q4'25
Q1'26
Q2'26
Q3'26
Q4'26
Q1'27
Q2'27
Ratios
Last 4 years, with trend
| Ratio | FY23 | FY24 | FY25 | FY26 | Trend |
|---|---|---|---|---|---|
| Debtor Days | 32 | 63 | 40 | 43 | |
| Inventory Days | 59 | 50 | 24 | 48 | |
| Payable Days | 74 | 71 | 69 | 66 | |
| Cash Conversion Cycle | 17 | 42 | -5 | 25 | |
| Working Capital Days | 16 | 44 | -5 | 27 | |
| ROCE % | 15.4 | 16.4 | 18.7 | 19.4 | |
| ROE % | 15 | 15.4 | 16.4 | 16.7 | |
| OPM % | 23.3 | 23.7 | 24.5 | 24.1 |
Statement figures on this page are illustrative demo data until this company is scraped by the data pipeline. For educational purposes only. Not investment advice.